Century Therapeutics Reports Strong Q1 2025 Financial Results

An announcement from Century Therapeutics ( (IPSC) ) is now available.

On May 15, 2025, Century Therapeutics reported its first-quarter financial results and provided a business update. The company initiated patient dosing in the Phase 1 CALiPSO-1 trial for CNTY-101 in the U.S., with plans to expand to Europe. Century is also preparing to start IND-enabling studies for CNTY-308 in mid-2025. Financially, the company reported a net income of $76.6 million for the quarter, significantly up from a net loss in the same period last year, largely due to collaboration revenue from a terminated agreement with Bristol-Myers Squibb.

The most recent analyst rating on (IPSC) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Century Therapeutics stock, see the IPSC Stock Forecast page.

Spark’s Take on IPSC Stock

According to Spark, TipRanks’ AI Analyst, IPSC is a Underperform.

Century Therapeutics faces significant financial challenges with ongoing losses despite revenue growth. Technical indicators show a bearish trend, and valuation metrics are unattractive, with high risk due to volatility. The overall score reflects these challenges, indicating a cautious outlook for investors.

To see Spark’s full report on IPSC stock, click here.

More about Century Therapeutics

Century Therapeutics (NASDAQ: IPSC) is a clinical-stage biotechnology company specializing in the development of induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancers. The company aims to create off-the-shelf cell therapies to improve patient access and advance the treatment of these conditions.

Average Trading Volume: 579,262

Technical Sentiment Signal: Sell

Current Market Cap: $45.32M

Find detailed analytics on IPSC stock on TipRanks’ Stock Analysis page.